Edition:
United States

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

7.95USD
20 Aug 2018
Change (% chg)

$-0.20 (-2.45%)
Prev Close
$8.15
Open
$8.10
Day's High
$8.10
Day's Low
$7.69
Volume
3,706
Avg. Vol
7,958
52-wk High
$15.19
52-wk Low
$4.84

Latest Key Developments (Source: Significant Developments)

Arcturus Says Founder Joseph Payne Reinstated As President And CEO
Thursday, 31 May 2018 07:00am EDT 

May 31 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS ANNOUNCES MANAGEMENT APPOINTMENTS; COMPANY FOUNDER JOSEPH E. PAYNE REINSTATED AS PRESIDENT AND CEO.ARCTURUS THERAPEUTICS LTD - PAD CHIVUKULA HAS BEEN REINSTATED AS CHIEF SCIENTIFIC OFFICER AND CHIEF OPERATING OFFICER.ARCTURUS THERAPEUTICS LTD - PETER FARRELL HAS BEEN NAMED AS CHAIRMAN OF BOARD OF DIRECTORS OF COMPANY.  Full Article

Amir Efrati Reports 5.3 Percent Stake In Arcturus Therapeutics
Monday, 30 Apr 2018 05:07pm EDT 

April 30 (Reuters) - Arcturus Therapeutics Ltd ::AMIR EFRATI - ON APRIL 27, SENT LETTER TO ISRAELI COURT SHOWING OPPOSITION TO TRANSACTION THEY BELIEVE ARCTURUS THERAPEUTICS BOARD HAS BEEN PURSUING.AMIR EFRATI REPORTS 5.3 PERCENT STAKE IN ARCTURUS THERAPEUTICS AS OF APRIL 27, 2018 - SEC FILING.AMIR EFRATI SAYS INTEND TO REVIEW INVESTMENT IN ARCTURUS THERAPEUTICS ON A CONTINUING BASIS.AMIR EFRATI SAYS PURCHASED ARCTURUS THERAPEUTICS' SHARES BASED ON BELIEF THAT SHARES, WHEN PURCHASED, WERE UNDERVALUED.  Full Article

Joseph Payne Says "Rejects" Arcturus Therapeutics' Board Of Directors' Latest Lawsuit Against Payne
Monday, 23 Apr 2018 09:30am EDT 

April 23 (Reuters) - Arcturus Therapeutics Ltd ::JOSEPH PAYNE SAYS "REJECTS" ARCTURUS THERAPEUTICS' BOARD OF DIRECTORS' LATEST LAWSUIT AGAINST PAYNE.JOSEPH PAYNE SAYS OWNS APPROXIMATELY 13.7% OF ISSUED AND OUTSTANDING SHARES OF ARCTURUS THERAPEUTICS.JOSEPH PAYNE SAYS URGES ARCTURUS THERAPEUTICS' BOARD TO SET DATE FOR THE EXTRAORDINARY GENERAL MEETING THAT PAYNE FILED FORMAL REQUEST FOR ON FEB 12.  Full Article

Bradley Thomas Sorenson Reports 5.6 Pct Stake In Arcturus Therapeutics As Of Nov. 16, 2017
Friday, 19 Jan 2018 06:10am EST 

Jan 19 (Reuters) - Bradley Thomas Sorenson: :BRADLEY THOMAS SORENSON REPORTS 5.6 PERCENT STAKE IN ARCTURUS THERAPEUTICS LTD AS OF NOVEMBER 16, 2017 - SEC FILING.BRADLEY THOMAS SORENSON - PURCHASED ARCTURUS THERAPEUTICS' SHARES BASED ON BELIEF THAT SUCH SECURITIES, WHEN PURCHASED, WERE "UNDERVALUED".  Full Article

Arcturus Announces Expansion Of Collaboration With Takeda
Wednesday, 17 Jan 2018 07:00am EST 

Jan 17 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS ANNOUNCES EXPANSION OF COLLABORATION WITH TAKEDA PHARMACEUTICALS TO DEVELOP RNA-BASED THERAPEUTICS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) AND OTHER GI DISORDERS.ARCTURUS THERAPEUTICS - TAKEDA, CO TO DEVELOP RNA-BASED THERAPEUTICS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, OTHER GASTROINTESTINAL.ARCTURUS - TO DEVELOP TREATMENT OF NASH AND GI RELATED DISORDERS USING CO'S LUNAR LIPID-MEDIATED DELIVERY SYSTEMS & UNA OLIGOMER CHEMISTRY.  Full Article

Arcturus and Curevac Enter Into Strategic Collaboration To Jointly Novel Messenger RNA Therapeutics
Thursday, 4 Jan 2018 07:00am EST 

Jan 4 (Reuters) - Arcturus Therapeutics Ltd ::CO, CUREVAC AG ENTER INTO STRATEGIC COLLABORATION TO JOINTLY DISCOVER, DEVELOP,COMMERCIALIZE NOVEL MESSENGER RNA THERAPEUTICS.DEVELOPMENT COSTS WILL BE SHARED BETWEEN COS,WITH PLANS TO CO-COMMERCIALIZE PRODUCTS IN FUTURE UNDER PROFIT SHARING ARRANGEMENT.  Full Article

Arcturus Therapeutics Ltd Says Raised About $67.8 Million In Equity Financing
Thursday, 4 Jan 2018 06:17am EST 

Jan 4 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS LTD SAYS RAISED ABOUT $67.8 MILLION IN EQUITY FINANCING .  Full Article

Alcobra qtrly ‍net loss per share $0.09​
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Alcobra Ltd :Alcobra announces third quarter 2017 financial results and provides corporate update.Alcobra Ltd - qtrly ‍net loss per share $0.09​.  Full Article

ARCTURUS, SYNTHETIC GENOMICS ANNOUNCE ALLIANCE TO DEVELOP VACCINES, THERAPEUTICS
Tuesday, 31 Oct 2017 08:00am EDT 

Oct 31 (Reuters) - Synthetic Genomics::ARCTURUS THERAPEUTICS AND SYNTHETIC GENOMICS ANNOUNCE STRATEGIC ALLIANCE TO DEVELOP NEXT-GENERATION VACCINES AND THERAPEUTICS.UNDER COLLABORATION, CO WILL HAVE EXCLUSIVE ACCESS TO LUNAR TECHNOLOGY FOR VACCINES AND THERAPEUTICS, USING SELF-AMPLIFYING RNA​.UNDER, COLLABORATION, ‍ARCTURUS WILL RECEIVE UPFRONT CASH PAYMENT, RESEARCH AND DEVELOPMENT SUPPORT, PRE-CLINICAL, DEVELOPMENT, SALES MILESTONE PAYMENTS.‍UNDER COLLABORATION, ARCTURUS WILL ALSO RECEIVE ROYALTY PAYMENTS ON ANY FUTURE SUBLICENSED PRODUCTS ​.  Full Article

Alcobr, Arcturus Therapeutics agree to merge
Wednesday, 27 Sep 2017 06:19pm EDT 

Sept 27 (Reuters) - Alcobra Ltd ::Alcobra ltd and Arcturus therapeutics, inc. Agree to merge.Proposed merger has been unanimously approved by boards of directors of both companies.Co, Arcturus therapeutics​ ‍sign definitive agreement to merge two companies in an all-stock transaction.Holders of arcturus outstanding capital stock immediately prior to merger will receive ordinary shares of alcobra in merger​.Conversion ratio for deal is based on a valuation of co of $46.7 million, including about $35 million of expected alcobra cash at closing​.Combined company well-capitalized with approximately $40 million in cash projected at closing.Joseph E. Payne is expected to serve as president and chief executive officer of combined company​.On pro forma basis for combined co,alcobra shareholders to own about 40%,arcturus shareholders expected to own about 60% of combined co.Board of directors of combined company will be comprised of seven members​.$40 million in cash projected at closing is expected to fund co through multiple value creation milestones and into early clinical development.Seven members will include three members to be designated by Alcobra and four members to be designated by Arcturus​.  Full Article

BRIEF-Amir Efrati Reports 5.3 Percent Stake In Arcturus Therapeutics

* AMIR EFRATI - ON APRIL 27, SENT LETTER TO ISRAELI COURT SHOWING OPPOSITION TO TRANSACTION THEY BELIEVE ARCTURUS THERAPEUTICS BOARD HAS BEEN PURSUING